Egypt’s Reme-D secures GIF backing to cut diagnostic costs by 40%
- Egypt-based biotech startup Reme-D has raised $500,000 from the Global Innovation Fund (GIF) to scale its molecular diagnostics solutions.
- Founded in 2022 by Salma Tammam, the company develops room-temperature PCR testing kits using nanotechnology and lyophilisation techniques.
- The technology eliminates cold-chain requirements, reducing diagnostic costs by up to 40% and improving reliability in low-resource settings.
- Reme-D currently operates across Egypt, Iraq, Sudan, and Kenya, serving 92 healthcare facilities and testing around 50,000 patients monthly.
- The funding will support expansion into Nigeria and Libya, production scaling, and R&D in genetic diseases, oncology, and maternal health.
Press release:
Egyptian biotech startup Reme-D has secured a $500,000 investment from the Global Innovation Fund (GIF) to expand its operations and scale accessible molecular diagnostics across Africa and the Middle East.
Founded in 2022, Reme-D develops PCR testing kits that remain stable at room temperature, eliminating the need for cold-chain logistics. By leveraging nanotechnology and lyophilisation techniques, the company enables cost-effective and reliable diagnostics in infrastructure-constrained environments.
The technology reduces operational costs by up to 40% while minimising reagent waste and improving testing reliability, particularly in regions with limited access to consistent electricity.
Reme-D has already established a growing footprint across Egypt, Iraq, Sudan, and Kenya, supporting 92 healthcare facilities and testing approximately 50,000 patients monthly. Its solutions have also reduced testing time by up to 70% in certain applications.
The new funding will support the company’s next phase of growth, including commercial expansion into Nigeria and Libya, scaling manufacturing capabilities, and advancing research into genetic diseases, oncology, and maternal health diagnostics.
Reme-D’s approach reflects a broader shift toward locally developed healthcare technologies designed to address real-world constraints, improving access to diagnostics across underserved populations.
